Comparison of the efficacy of ciclesonide 160 μg QDand budesonide 200 μg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study

Niphadkar, Pramod V.; Jagannath, K; Joshi, Jyotsna M; Awad, Nilkanth Tukaram; Boss, Hildegard; Hellbardt, S.; Gadgil, Durga

doi:10.1016/j.clinthera.2005.11.005

Cited by 44 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results presented are for ITT analysis, unless stated otherwise. 196 did not report changes from baseline FEV 1 for the three treatment groups, but did report the LS mean difference between the groups' changes from baseline. The difference between patients who received 200 µg CIC in the morning and patients in the 400 µg/day BUD group was -0.036 litres (95% CI -0.120 to 0.045).…”

Section: Resultsmentioning

confidence: 99%

“…One RCT, 196 published in 2005, evaluated the effectiveness of CIC compared with BUD (Table 18). An unpublished report containing more extensive results for this trial was made available to us by the manufacturer but is considered commercial in confidence.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Niphadkar and colleagues 196 assessed asthma symptoms using a five-point scale (0 = no symptoms, 4 = awake most of the night or unable to perform daily activities; no reference given for scale). The percentages of symptom-free days were 89, 91 and 93% for the morning CIC, evening CIC and BUD groups, respectively (p = not significant for both comparisons with BUD).…”

Section: Symptomsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Shepherd¹,

Rogers²,

Anderson³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These sugges...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Symptomsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Shepherd¹,

Rogers²,

Anderson³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…[15] In addition, a study comparing the effects of ciclesonide 320 µg and budesonide 400 µg once daily when administered in the morning showed that ciclesonide was at least as effective as budesonide in patients with persistent asthma. [16] Ciclesonide was non-inferior to budesonide for FEV 1 , and statistically superior to budesonide (p=0.010) for FVC.…”

Section: Discussionmentioning

confidence: 99%

“…[14] In a comparative study, ciclesonide 160 µg administered once daily, either in the morning or evening, was shown to be comparable to budesonide 200 µg twice daily (400 µg per day) in maintaining lung function, asthma symptoms and rescue-medication use. [15] A further study compared the effects of a similar dose of ciclesonide (320 µg) and budesonide (400 µg) once-daily. Due to the circadian fluctuations in asthma, it is important to determine the effects of ICS at different times of the day.…”

Section: Introductionmentioning

confidence: 99%

Ciclesonide is more effective than budesonide in the treatment of persistent asthma

Ukena

Biberger²,

Steinijans³

et al. 2007

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Background: Ciclesonide is a lung-activated inhaled corticosteroid that provides effective control of persistent asthma. The objective of this study was to compare the efficacy and safety of once-daily ciclesonide versus once-daily budesonide in patients with asthma. Methods:A total of 399 patients with asthma were randomised to receive once-daily ciclesonide 320 µg ex-actuator (equivalent to 400 µg ex-valve) or once-daily budesonide 400 µg for 12 weeks. The primary endpoint was forced expiratory volume in 1 second (FEV 1 ). Additional efficacy variables included forced vital capacity (FVC), peak expiratory flow (PEF), asthma symptoms, use of rescue medication and time to onset of effect. Adverse events were monitored throughout the study. Conclusion:Once-daily ciclesonide was more effective than once-daily budesonide in improving FEV 1 , FVC and PEF. Ciclesonide also had an earlier onset of action than budesonide in patients with persistent asthma. Both ciclesonide and budesonide had good safety and tolerability profiles.

show abstract

Ciclesonide versus other inhaled steroids for chronic asthma in children and adults

Manning

Gibson

Lasserson

2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

The results of this review give some support to ciclesonide as an equivalent therapy to other ICS at similar nominal doses. The studies assessed low doses of steroids, in patients whose asthma required treatment with low doses of steroids. At half the dose of FP and BDP/BUD, the effects of ciclesonide were more inconsistent The effect on candidiasis may be of importance to people who find this to be problematic. The role of ciclesonide in the management of asthma requires further study, especially in paediatric patients. Further assessment against FP at a dose ratio of 1:2 is a priority.

show abstract

Comparison of the efficacy of ciclesonide 160 μg QDand budesonide 200 μg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study

Cited by 44 publications

References 17 publications

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Ciclesonide is more effective than budesonide in the treatment of persistent asthma

Ciclesonide versus other inhaled steroids for chronic asthma in children and adults

Contact Info

Product

Resources

About